{"id":900940,"date":"2025-10-28T07:52:09","date_gmt":"2025-10-28T11:52:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/"},"modified":"2025-10-28T07:52:09","modified_gmt":"2025-10-28T11:52:09","slug":"ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/","title":{"rendered":"Ocular Therapeutix\u2122 to Report Third Quarter 2025 Financial Results on November 4, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BEDFORD, Mass., Oct.  28, 2025  (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, November 4, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2025.<\/p>\n<p>\n        <strong>Conference Call and Webcast Information:<\/strong>\n      <\/p>\n<p>Date: Tuesday, November 4, 2025, at 8:00 AM ET<\/p>\n<p>Participant Dial-In (U.S.): 1-877-407-9039<\/p>\n<p>Participant Dial-In (International): 1-201-689-8470<\/p>\n<p>Webcast Access: Please click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=18t1tPeWoHZ5NSAZ5XWBSbLJWLXaH7mlhq-5f719STL0YcDkfz9LB5WjJDoOdF_aqPkmwFDsf-6QXM_9Izxenthp8LYcM_I9xDl3pthGj_G1j8xaBiOAZlrT3GKlqAyupEEWWYBt6BAPTRcykJHoDA==\" rel=\"nofollow\" target=\"_blank\">here<\/a><\/p>\n<p>The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.<\/p>\n<p>\n        <strong>About Ocular Therapeutix, Inc.<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI\u2122 (also known as OTX-TKI), Ocular\u2019s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX\u2122 proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), with a Phase 3 clinical program for non-proliferative diabetic retinopathy (NPDR) planned to be initiated imminently.<\/p>\n<p>Ocular\u2019s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA<sup>\u00ae<\/sup>, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.<\/p>\n<p>Explore the Company\u2019s new corporate branding and follow the Company on its website, LinkedIn, or X.<\/p>\n<p>DEXTENZA<sup>\u00ae<\/sup> is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI\u2122, ELUTYX\u2122, and Ocular Therapeutix\u2122 are trademarks of Ocular Therapeutix, Inc.<\/p>\n<p>\n        <strong>Investors &amp; Media<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc.<br \/>Bill Slattery<br \/>Vice President, Investor Relations<br \/>bslattery@ocutx.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MzEyNSM3MjI4MDU3IzIwMTEwNTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzczYzkwNDUtNDI1Ni00M2MxLTk3ZjAtNmNiNDA5NjVmNjUzLTEwMjI2MjktMjAyNS0xMC0yOC1lbg==\/tiny\/Ocular-Therapeutix-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, November 4, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2025. Conference Call and Webcast Information: Date: Tuesday, November 4, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1-877-407-9039 Participant Dial-In (International): 1-201-689-8470 Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ocular Therapeutix\u2122 to Report Third Quarter 2025 Financial Results on November 4, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-900940","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocular Therapeutix\u2122 to Report Third Quarter 2025 Financial Results on November 4, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocular Therapeutix\u2122 to Report Third Quarter 2025 Financial Results on November 4, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, November 4, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2025. Conference Call and Webcast Information: Date: Tuesday, November 4, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1-877-407-9039 Participant Dial-In (International): 1-201-689-8470 Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will &hellip; Continue reading &quot;Ocular Therapeutix\u2122 to Report Third Quarter 2025 Financial Results on November 4, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-28T11:52:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MzEyNSM3MjI4MDU3IzIwMTEwNTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocular Therapeutix\u2122 to Report Third Quarter 2025 Financial Results on November 4, 2025\",\"datePublished\":\"2025-10-28T11:52:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\\\/\"},\"wordCount\":338,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2MzEyNSM3MjI4MDU3IzIwMTEwNTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\\\/\",\"name\":\"Ocular Therapeutix\u2122 to Report Third Quarter 2025 Financial Results on November 4, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2MzEyNSM3MjI4MDU3IzIwMTEwNTY=\",\"datePublished\":\"2025-10-28T11:52:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2MzEyNSM3MjI4MDU3IzIwMTEwNTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2MzEyNSM3MjI4MDU3IzIwMTEwNTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocular Therapeutix\u2122 to Report Third Quarter 2025 Financial Results on November 4, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocular Therapeutix\u2122 to Report Third Quarter 2025 Financial Results on November 4, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/","og_locale":"en_US","og_type":"article","og_title":"Ocular Therapeutix\u2122 to Report Third Quarter 2025 Financial Results on November 4, 2025 - Market Newsdesk","og_description":"BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, November 4, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2025. Conference Call and Webcast Information: Date: Tuesday, November 4, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1-877-407-9039 Participant Dial-In (International): 1-201-689-8470 Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will &hellip; Continue reading \"Ocular Therapeutix\u2122 to Report Third Quarter 2025 Financial Results on November 4, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-28T11:52:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MzEyNSM3MjI4MDU3IzIwMTEwNTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocular Therapeutix\u2122 to Report Third Quarter 2025 Financial Results on November 4, 2025","datePublished":"2025-10-28T11:52:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/"},"wordCount":338,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MzEyNSM3MjI4MDU3IzIwMTEwNTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/","name":"Ocular Therapeutix\u2122 to Report Third Quarter 2025 Financial Results on November 4, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MzEyNSM3MjI4MDU3IzIwMTEwNTY=","datePublished":"2025-10-28T11:52:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MzEyNSM3MjI4MDU3IzIwMTEwNTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MzEyNSM3MjI4MDU3IzIwMTEwNTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-third-quarter-2025-financial-results-on-november-4-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocular Therapeutix\u2122 to Report Third Quarter 2025 Financial Results on November 4, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/900940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=900940"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/900940\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=900940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=900940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=900940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}